WEKO3
アイテム
HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法
https://repo.qst.go.jp/records/66013
https://repo.qst.go.jp/records/66013902e5458-d640-498c-8039-767ef58e85c6
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-11-09 | |||||
| タイトル | ||||||
| タイトル | HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法 | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
李, 惠子
× 李, 惠子× 長谷川, 純崇× 李 惠子× 長谷川 純崇 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT), the internal radiotherapy using radioisotope (RI)-labeled cancer specific antibody, has huge advantage in targeting metastatic cancer. Recently, alpha-RIT, using alpha emitting RI, is getting higher attention, because the alpha particle has high cell cytotoxicity and its short range can prevent damages to untargeted tissues. Astatine 211 (<SUP>211</SUP>At) is one of the useful alpha-RI. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with <SUP>211</SUP>At-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with <SUP>211</SUP>At-trastuzumab as a new effective therapeutic for HER2+ PMGC. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第75回日本癌学会学術総会 | |||||
| 発表年月日 | ||||||
| 日付 | 2016-10-07 | |||||
| 日付タイプ | Issued | |||||
